El-Khoueiry, Anthony BAnthony BEl-KhoueiryMeyer, TimTimMeyerANN-LII CHENGRimassa, LorenzaLorenzaRimassaSen, SuvajitSuvajitSenMilwee, StevenStevenMilweeKelley, Robin KateRobin KateKelleyAbou-Alfa, Ghassan KGhassan KAbou-Alfa2023-01-122023-01-122022-04-091471-2407https://scholars.lib.ntu.edu.tw/handle/123456789/627209Patients with hepatocellular carcinoma (HCC) and Child-Pugh B liver cirrhosis have poor prognosis and are underrepresented in clinical trials. The CELESTIAL trial, in which cabozantinib improved overall survival (OS) and progression-free survival (PFS) versus placebo in patients with HCC and Child-Pugh A liver cirrhosis at baseline, was evaluated for outcomes in patients who had Child-Pugh B cirrhosis at Week 8.enCabozantinib; Child–Pugh B; Hepatocellular carcinoma[SDGs]SDG1[SDGs]SDG3Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child-Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trialjournal article10.1186/s12885-022-09453-z353975082-s2.0-85127886113WOS:000781372200010https://api.elsevier.com/content/abstract/scopus_id/85127886113